Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
National Institute For Bioprocessing Research And Training maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates a very focused point of interaction with the USPTO, as all current prosecution activity is limited to a single pending matter. This activity is situated within 1 distinct art unit.
The busiest examiner for this portfolio is NGUYEN, PETER, who is responsible for 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner is the sole individual currently evaluating the company's claims. The alignment of 1 pending office action with 1 distinct examiner and 1 distinct art unit suggests a highly specific technological focus for the current filings.
For a patent practitioner, this concentration means that the immediate success of the portfolio depends entirely on the feedback from NGUYEN, PETER. There are no other distinct examiners or distinct art units available within the data to provide a comparative baseline for prosecution performance. The single art unit involved will dictate the procedural and technical standards that the institute must meet to secure its biotechnology and pharmaceutical patents.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, PETER | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030487 | METHOD AND SYSTEM FOR PREDICTING THE PERFORMANCE OF BIOPHARMACEUTICAL MANUFACTURING PROCESSES | NGUYEN, PETER | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030487 | METHOD AND SYSTEM FOR PREDICTING THE PERFORMANCE OF BIOPHARMACEUTICAL MANUFACTURING PROCESSES | NGUYEN, PETER | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Institute For Bioprocessing Research And Training has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Peter Nguyen has the most, with 1 of National Institute For Bioprocessing Research And Training's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.